Hiroshi Tomiyama

This inventor holds 21 USPTO granted patents and 4 published patent applications, plus 2 CIPO patents and 7 EPO patents, primarily in Heterocyclic Compounds. Top assignees: Kotobuki Pharmaceutical Co Ltd, Astellas Pharma Gmbh, Kotobuki Pharmaceutical Co., Ltd.. Active years: 2002-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hiroshi Tomiyama. Retrieved from https://idiyas.com/inventor/hiroshi-tomiyama

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 (Patent Applications = 4)

% Patents Active = 42.9

CIPO Patents = 2

EPO Patents = 7 (Patent Applications = 8)

Average Co-Inventor Count = 5.5

ph-index = 8

Forward Citations = 328(Granted Patents)

Location History:

Hanishina-gun, JP (2002 - 2003)
Nagano-ken, JP (2003 - 2005)
Tokyo, JP (2010 - 2011)
Sakaki-machi, JP (2010 - 2011)
Chuo-ku, JP (2016)
Nagano, JP (2005 - 2024)

Company Filing History:

18 out of 27

Kotobuki Pharmaceutical Co Ltd

Kotobuki Pharmaceutical Co., Ltd.

patent

4. 1 out of 2

Kotobuki Pharmaceuticals Co., Ltd.

patents

5. 1 out of 1

Nico Therapeutics, Inc.

patent

where one patent can have more than one assignee

Years Active: 2002-2026

Loading Chart...

Areas of Expertise:

Triazine Compound

Carboxamide Compound

Pyridazinyl-Thiazolecarboxamide

Diamino Heterocyclic

Nitrogen-Containing

C-Glycoside Derivatives

Optically Active Alcohols

Cholesterol Lowering Agent

Hyperphosphatemia

Azulene Derivatives

Antidiabetic Agents

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12692241 - Substituted triazine compound (2026-07-28),

2. 12655122 - Heteroaryl carboxamide compound (2026-06-16),

3. 12227517 - Pyridazinyl-thiazolecarboxamide compound (2025-02-18),

4. 12077519 - Heteroaryl carboxamide compound (2024-09-03),

5. 9487491 - Diamino heterocyclic carboxamide compound (2016-11-08),

6. 9464077 - Nitrogen-containing aromatic heterocyclic compound (2016-10-11),

7. 8969336 - Diamino heterocyclic carboxamide compound (2015-03-03),

8. 8044206 - Nitrogen—containing heterocyclic derivatives having 2,6-disubstituted styryl (2011-10-25),

9. 7977466 - C-glycoside derivatives and salts thereof (2011-07-12),

10. 7956182 - Process for preparing optically active alcohols (2011-06-07),

11. 7795229 - Serum cholesterol lowering agent or preventative or therapeutic agent for atherosclerosis (2010-09-14),

12. 7772407 - C-glycoside derivatives and salts thereof (2010-08-10),

13. 7691898 - Phosphonic acid derivatives and the treating agents of diseases related hyperphosphatemia (2010-04-06),

14. 7202350 - C-glycoside derivatives and salts thereof (2007-04-10),

15. 7169761 - Azulene derivatives and salts thereof (2007-01-30),

Title: Hiroshi Tomiyama: Pioneering Innovations in Cancer Treatment

Introduction: Hiroshi Tomiyama, a visionary inventor hailing from Nagano, Japan, has made significant contributions to the field of healthcare with his groundbreaking patents and inventions. With a total of 17 patents to his name, Tomiyama's work has been instrumental in developing cutting-edge solutions for cancer treatment.

Latest Patents:

1. Diamino Heterocyclic Carboxamide Compound: Tomiyama's invention of this compound has proven to be a potent inhibitor against the kinase activity of the EML4-ALK fusion protein. This compound shows promising potential as a pharmaceutical composition for the prevention and treatment of various forms of cancer, including lung cancer.

2. Nitrogen-Containing Aromatic Heterocyclic Compound: Another remarkable invention by Tomiyama, this compound serves as a prophylactic and therapeutic agent for bladder cancer. Its inhibitory action on FGFR1, FGFR2, and FGFR3, especially mutant FGFR3, positions it as a valuable asset in the treatment of cancers related to these receptors.

Career Highlights: Throughout his career, Hiroshi Tomiyama has worked with esteemed companies such as Kotobuki Pharmaceutical Co Ltd and Astellas Pharma GmbH. His innovative spirit and dedication to advancing healthcare technologies have garnered him recognition as a key player in the industry.

Collaborations: Tomiyama's collaborative efforts with esteemed colleagues like Atsushi Noda and Yoshinori Kobayashi have further amplified the impact of his inventions. Together, they have pushed the boundaries of cancer research and treatment, paving the way for novel therapeutic interventions.

Conclusion: Hiroshi Tomiyama stands at the forefront of innovation in the realm of cancer treatment, with his pioneering inventions shaping the future of healthcare. His patents not only reflect his scientific acumen but also his unwavering commitment to improving patient outcomes and revolutionizing the field of oncology. Tomiyama's legacy serves as an inspiration to aspiring inventors, urging them to dream big and embark on a journey of discovery and invention that has the power to transform lives.

Profile summary based on public USPTO records.